Methods of prognosing a rheumatoid arthritis remission phenotype
AssigneeProgenika Biopharma, S.A.
InventorsArrate Eguiara, Diego Tejedor Hernández, Antonio Martínez Martínez, Laureano Simón Buela
Life of this patent
Estimating the term…
Abstract
A method for prognosing a rheumatoid arthritis phenotype using the outcomes of selected single nucleotide polymorphisms (SNPs) and clinical variables. A method for genotyping multiple rheumatoid arthritis associated genetic variations comprising use of a DNA microrarray. A microarray for use in the described methods.
Claims20
A method of prognosing a rheumatoid arthritis (RA) remission phenotype in a subject comprising:
- genotyping a sample obtained from the subject at one or more positions of single nucleotide polymorphism selected from the remission SNPs in Table 12;
- and
- determining that the subject has the RA remission phenotype if the genotype of the subject comprises one or more of the remission SNPs in Table 12, wherein the RA remission phenotype comprises at least 5 years of remission.
A method of prognosing a rheumatoid arthritis (RA) remission phenotype in a subject comprising:
- genotyping a sample obtained from the subject at one or more positions of single nucleotide polymorphism selected from the remission SNPs in Table 12;
- and
- determining that the subject is likely to have the RA remission phenotype if the genotype of the subject comprises one or more of the remission SNPs in Table 12.
A method of prognosing a rheumatoid arthritis (RA) remission phenotype in a subject comprising:
- genotyping a sample obtained from the subject at one or more positions of single nucleotide polymorphism selected from the remission SNPs in Table 12;
- determining a binary representation of the level of anti-cyclic citrullinated peptide antibody (ANTI-PCC BI) in a serum sample from the subject;
- and
- determining that the subject is likely to have the RA remission phenotype if the genotype of the subject comprises one or more of the remission SNPs in Table 12 and determining that the subject has the RA remission phenotype if the ANTI-PCC BI comprises the ANTI-PCC BI in Table 11A, wherein the remission phenotype comprises at least 5 years of remission.
Dependencies are inferred from the claim text.